Primer, we outline the current understanding of ARF and RHD pathogenesis and treatment, with a par ticular focus on heart disease, and we highlight future research priorities.
Epidemiology

Burden of disease
A 2005 systematic review, carefully designed to avoid overestimating the disease burden of GAS infection, concluded that there were approximately 471,000 cases of ARF each year (336,000 in children aged 5-14 years), 15.6-19.6 million prevalent cases of RHD and approxi mately 350,000 annual deaths as a result of ARF or RHD; almost all deaths occurred in lowincome and middle income countries 6 . The Global Burden of Disease (GBD) study more recently estimated that there are 33 million prevalent cases of RHD, causing more than 9 million DisabilityAdjusted Life Years lost and 275,000 deaths each year [7] [8] [9] (FIG. 1) .
Risk factors
Age. The incidence of initial cases of ARF is highest in children aged 5-14 years, although first episodes do occur in younger children, with reported cases of ARF in those as young as 2-3 years old 10, 11 . Initial episodes can also occur in older adolescents and adults, although cases in people >30 years of age are rare. By contrast, recurrent episodes often affect slightly older children, adolescents and young adults but are rarely observed beyond the age of 35-40 years.
RHD is a chronic disease caused by accumulated heart valve damage from a single severe or, more com monly, multiple recurrent ARF episodes. This means that, although RHD occurs in children, its prevalence peaks in adulthood, usually between the ages of 25 years and 45 years 10 .
Sex. In most populations, ARF is equally common in males and females. However, RHD occurs more commonly in females, with a relative risk of 1.6 to 2.0 compared with males. In addition, these sex differ ences might be stronger in adolescents and adults than in children 10, 12 . The reasons for this association are not clear, but intrinsic factors such as greater autoimmune susceptibility, as observed in systemic lupus erythema tosus 13 , and extrinsic factors such as greater exposure to GAS infection in women than in men as a result of closer involvement in childrearing might explain this differ ence. In addition, women and girls might experience reduced access to primary and secondary ARF prophy laxis compared with men and boys, and this could also contribute to differences in RHD rates between females and males. Finally, RHD in pregnancy is becoming increasingly recognized. Indeed, data from South Africa and Senegal suggest that RHD is a leading cause of indirect obstetric death, which in turn accounts for 25% of all maternal deaths in developing countries [14] [15] [16] . This effect relates to the worsening of preexisting disease as a result of haemodynamic changes that occur during preg nancy, rather than any increase in susceptibility to ARF or RHD because of pregnancy 17 .
Environmental factors. The vast majority of differences in risk between populations around the world can be explained by environmental factors. The relative con tribution of each of these individual risks is difficult to elucidate given that many of them overlap and most are associated with poverty and economic disadvantage 12, [18] [19] [20] . Household overcrowding is perhaps the best described risk factor and reduced overcrowding has been cited as one of the most important factors underlying the decline in ARF incidence in wealthy countries during the twen tieth century 21 . Recent data clearly show an association of ARF and RHD with household crowding 20, 22, 23 (see discussion on primordial prevention below).
In most studies, the risk of developing RHD is found to be highest in rural locations. For example, Indigenous Australians who live in remote communities are 3.3 times more likely to develop ARF than Indigenous Australians living in urban centres in the same region 24 . Similar findings have been reported from other regions, although in some studies the risk has been highest of all in urban slums 18, 20 . It is likely that these locations are proxy measures of other risk factors such as household crowding -which is greatest in urban slums but often high in poor, rural communities -and access to medi cal services. There have been several studies, dating back to some carried out in the United States during the 1960s and 1970s, that have shown lower rates of ARF in set tings that had improved access to medical care than in communities in which access to care was lower 25 . In sev eral regions, including the French Caribbean and Cuba, a reduction in ARF rates was associated with comprehen sive medical programmes that included a range of educa tion and health promotions as well as medical strategies targeting ARF and RHD. As a result, it is difficult to iso late the specific component of access to medical care that contributes to ARF and RHD reduction 26, 27 . Other individual associations of environmental fac tors with ARF and RHD, such as undernutrition, have been occasionally shown but the evidence linking them to the diseases is not strong 18 . Conversely, there is little doubt that the major associations with ARF and RHD relate to poverty and that these are classic diseases of social injustice 19 . Indeed, recent data from the Central Asian republics highlight how RHD can rapidly emerge in settings of social disruption, which suggests that social instability and wars play a major part in fostering ARF and RHD, probably through displacement, crowding and poor living conditions 28 . Of all of the environmental risk factors, overcrowded housing is the bestdescribed factor that is amenable to improvement.
Mechanisms/pathophysiology Overview After GAS infection of the pharynx, neutrophils, macro phages and dendritic cells phagocytose bacteria and present antigen to T cells. Both B and T cells respond to the GAS infection, initially by antibody production (IgM and IgG) and subsequently through T cell acti vation (mainly CD4 + cells). In susceptible individuals, the host response against GAS will trigger autoimmune reactions against host tissues (for example, the heart, brain, joints and/or skin) mediated by both Streptococcus spp.specific antibodies and T cells through a process called molecular mimicry (FIG. 2) . Molecular mimicry is the sharing of antibody or T cell epitopes between the host and the microorganism -infections generate antibodies or T cells against the infectious pathogen to clear the infection from the host and these antibodies and T cells also recognize host antigens. In the case of ARF, these host antigens are located in tissues such as the heart and the brain [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . The crossreactive immune response results in tran sient migratory polyarthritis as a result of the forma tion of immune complexes (FIG. 3) , leads to Sydenham's chor ea as the antibodies bind to basal ganglia and neuro nal cells (FIG. 4) , causes erythema marginatum and sub cutaneous nodules in the skin as antibodies bind to keratin (FIG. 5) and leads to inflammation of both heart valves and the myocardium (FIG. 6) . Although the myo cardium heals following this inflammation, there can be permanent damage to the valves, which leads to RHD. Diversification of the immune response against an immunodominant epitope leads to its amplification (epitope spreading), which favours the recog nition of several self antigens and facilitates tissue damage 41 . In this section, we describe rheumatic carditis (inflammation of the heart) and Sydenham's chorea ( inflammation of the basal ganglia). The rarer skin manifestation erythema marginatum might be due to antibodies against group A carbohydrate crossreacting with keratin 42, 43 and the sub cutaneous nodules that sometimes form in ARF might be granulomatous lesions that develop in the dermis of the skin as a result of delayed hypersensitivity against GAS antigens. Moreover, the formation of these nod ules might be driven by similar mechanisms to Aschoff bodies, which are granulomatous lesions that form in the heart valve.
Genetic susceptibility and group A Streptococcus
Both the features of host susceptibility and the genetic makeup of the streptococcal strain are crucial to the host-streptococcal interactions that result in auto immunity and in the development of ARF. This has been shown by the changing characteristics of ARF over time. For instance, GAS strains isolated during ARF epidemics of the World War II era were rich in M protein, heavily encapsulated by hyaluronic acid and highly viru lent in mice 44 . These strains, notable for their highly mucoidappearing colonies, primarily infected the throat rather than the skin and were also detected during ARF outbreaks in Utah in the United States towards the end of the twentieth century 45 . GAS strains isolated more recently in tropical climates do not share these characteristics. Indeed, molecular epidemio logical studies suggest a greater diversity of GAS strains in tropical regions, with skinassociated strains dominat ing, raising the possibility that skinassociated strains are also linked to cases of ARF [46] [47] [48] [49] [50] . This change in the association of particular strains of GAS with ARF could be due to selective pressures act ing on both the host and the organism. The evolution of GAS strains over years of penicillin therapy and prophy laxis might have led to ARF cases that were caused by GAS strains that do not have the same characteristics that were reported in previous ARF outbreaks in the United States many decades ago. In addition, the host might have evolved over this period, as many children who contracted the disease in industrialized countries in the ARF epidemics of the early to midtwentieth century did not survive or were not physically able to bear offspring. In this context, the most severe genetic predispositions for ARF susceptibility might have been transferred to the next generation at a much lower fre quency than they were in nonepidemic settings. These changes over the past 100 years might have changed the bacterium and the host and, together with reduced exposure to GAS as a result of improved living condi tions, might have been responsible for the decline in overall rates and the reduction in epidemics of ARF in industrialized countries.
How these factors may have influenced ARF in devel oping countries is even more uncertain. The extreme rates of RHD seen in the poorest countries have only become evident in recent decades, although high rates of ARF and poststreptococcal glomerulonephritis were well documented in Trinidad as far back as the 1960s 51 and population prevalence rates of RHD between 0.5% and 2.2% were documented in the same period in India, Pakistan and Iran (reviewed in REF. 5 ). It seems likely that high rates of ARF and RHD have been mainly unrepor ted in developing countries for at least half a century, and the lack of availability of treatment for severe RHD means that premature mortality from RHD is high 52 . Given the ongoing high rates of ARF and RHD in develop ing countries, any selective pressure on host susceptibility caused by premature mortality seems not to have had a substantial effect in these places. However, it is quite possible that selective pressures on organism factors in developing countries might be affected by those in industrial ized nations, given emerging evidence of mobility of GAS strains on a global scale 53 .
Genetics of host susceptibility are also important. Studies of families with individuals who were suscepti ble to ARF found that this susceptibility was herit able and that the associated loci had limited penetrance. In addition, phenotypic concordance among dizygotic twins suggests that susceptibility to ARF has an inheri ted component but that this inheritance does not follow a classic Mendelian pattern 54 . Polymorphisms in several genes coding for immunerelated proteins have been associated with ARF and RHD susceptibility. These pro teins include mannosebinding protein C 2 (encoded by MBL2), ficolin 2 (encoded by FCN2), lowaffinity immunoglobulin γ Fc region receptor IIa (encoded by FCGR2A), Tolllike receptor 2 (encoded by TLR2), tumour necrosis factor (encoded by TNF), interleukin1 receptor antago nist (encoded by IL1RN), transforming growth factor β1 (encoded by TGFβ1) and cytotoxic T lymphocyte protein 4 (encoded by CTLA4) (TABLE 1) .
Class II human leukocyte antigen (HLA) molecules are expressed on the surface of antigenpresenting cells (APCs) and are crucial for triggering adaptive immune responses via the T cell receptor. HLA class II alleles have been associated with ARF and RHD around the world; the DR7 allele is the most frequently associated with the conditions 54, 82 (TABLE 1) . In addition, the class I HLA allele HLA*B5 is associated with developing ARF and the formation of immune complexes during ARF 83 . These associations indicate that genetic alterations of the Fc receptor (FcR) genes and the potential for failure of clearance of immune complexes might play an impor tant part in disease pathogenesis. Further understanding of genetic susceptibility to ARF is likely to come from large multiethnic genome studies rather than studies from a single region. 10-20% decrease  5-10% decrease  <5% decrease  <5% increase  5-10% increase  10-20% increase  >20% increase  No data available   Change in agestandardized prevalence  of RHD (1990-2013) <50,000 <100,000 <500,000 <1,000,000 <2,500,000 <5,000,000 <8,000,000 >8,000,000
>20% decrease
Number of prevalent cases of RHD (2013) Nature Reviews | Disease Primers 
Humoral immune response
The humoral (antibodymediated) immune response to GAS is mainly responsible for initiating rheumatic carditis. This carditis is followed by cellular infiltration of the endocardium and valve tissues, which results in further damage that leads to RHD 35, 84, 85 . The humoral response can also lead to Sydenham's chorea, which involves lympho cytic perivascular cuffing of vessels in the brain and which may occur with or without cardi tis 86 . Antibodies against Streptococcus spp. that cross react with antigens found in the heart or in the brain have been identified in the sera of patients with ARF and in the sera of rabbits and mice that had been immunized against streptococcal infection [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . The method for pro ducing monoclonal antibodies (mAbs) enables produc tion and identification of crossreactive Streptococcus spp.specific mAbs derived from mice and humans with ARF that are heartspecific and brain specific. These developments facilitated the discovery of the patho genetic mechanisms that are mediated by autoantibodies produced during ARF, including their effects on proteins in the heart and the brain.
The hypothesis of molecular mimicry occurring between GAS, heart and brain antigens is supported by evidence from studies using human mAbs 35, 38 , human serum IgG antibodies and both peripheral 33 and intra lesional 34 T cell clones from patients with ARF and RHD 32 . A model of ARF affecting both the heart and the brain was developed in Lewis rats and studies using this model have shown that immunization with GAS anti gens leads to valvulitis 87 or behaviours similar to those in Sydenham's chorea 30 . The investigation of Streptococcus spp.specific mouse mAbs 40 and human mAbs derived from those with rheumatic carditis 35 and Sydenham's chorea 38 has supported the hypothesis that antibodies against the group A carbohydrate epitope Nacetyl βdglucosamine recognize crossreactive structures on heart valve endothelium and/or endocardium and on neuronal cells, which could cause carditis or Sydenham's chorea, respectively.
Sydenham's chorea. Sydenham's chorea is the neuro logical manifestation of ARF and is characterized by chorea and neuropsychiatric symptoms 88 . In Sydenham's chorea, neuronspecific antibodies (immuno globulin G (IgG)) target basal ganglia 36 and cause the release of excess dopamine from neuronal cells in culture 38 . Human mAbs derived from patients with Sydenham's chorea 38 react by molecular mimicry with the group A carbohydrate epitope Nacetylβdglucosamine and a group of antigens found in the basal ganglia includ ing the D1 and D2 dopamine receptors 31 , lysoganglio side 38 and tubulin 37 . The crossreactive neuronspecific antibodies are generated by the response against the group A streptococcal carbohydrate and recognize both host and microbial antigens, which share a structure that is similar enough for the antibody to crossreact. Although the reasons for antibody targeting of the basal ganglia are not well known, specific antibody targeting might be due to the presence of dopamine D2 receptors on dopa minergic neurons in the substantia nigra and ventral tegu mental area that project to the striatum 89 . Localization of such targeted neurons was observed when a human Sydenham's choreaderived mAb was expressed in transgenic mice 31 . A general theme in immunological mimicry by anti bodies is the recognition of an intracellular antigen that is a biomarker; by contrast, antigens at the cell surface control disease mechanisms, such as cell signalling or complementdependent cytotoxicity. Indeed, there is evidence that crossreactive antibodies generated dur ing ARF can have functional, and potentially patho genetic, consequences for neuronal cells. Antigens such as lysoganglioside and dopamine receptors in the neuronal cell membrane bind antibody and change cellular biochemistry and signalling through activa tion of calcium/calmodulindependent protein kinase type II (CAMK2), which leads to an increase in tyrosine hydroxylase and dopamine release 31, 39, 90 . This altered signalling might function as a mechanism in disease 90, 91 ( FIG. 4) . For instance, human mAbs, serum IgG anti bodies and/or cerebrospinal fluid from patients with Sydenham's chorea activate CAMK2 (REF. 38) in human neuronal cells and increase 3 Hdopamine release from human neuronal cells 39 . CAMK2 activation in neuronal cells was also shown using patient serum, and removal of IgG from the serum abrogated CAMK2 activation 30, 38 , which indicates that this neuronal signalling is anti body dependent. In addition, a human mAb derived from a patient with Sydenham's chorea induced tyro sine hydroxylase activity in dopaminergic neurons after passive transfer into rat brains 39 , which suggests that the Nature Reviews | Disease Primers Following group A Streptococcus (GAS) adhesion to and invasion of the pharyngeal epithelium, GAS antigens activate both B and T cells. Molecular mimicry between GAS group A carbohydrate or serotype-specific M protein and the host heart, brain or joint tissues can lead to an autoimmune response, which causes the major manifestations of acute rheumatic fever (ARF). BCR, B cell receptor; TCR, T cell receptor. neuronspecific antibodies formed in Sydenham's chorea might lead to neuronal changes and manifestations of disease. Furthermore, one study showed that when vari able genes encoding a mAb derived from a patient with Sydenham's chorea, mAb 24.3.1, were expressed in transgenic mice, the resulting antibodies targeted dopaminergic tyrosine hydroxylaseexpressing neurons in basal ganglia 31 (FIG. 7) . In addition, the whole mAb 24.3.1 and the source serum reacted with and signalled through the human dopamine D2 receptor 31 . Other antibodies have been found to react with the human D1 dopamine receptor and the ratio of dopamine D1 receptorspecific to dopamine D2 receptorspecific anti bodies in Sydenham's chorea correlates with a measure of symptom severity 29 . Finally, plasmapheresis, in which patients with Sydenham's chorea receive plasma from healthy donors, leads to the improvement of symp toms 92, 93 . This finding strongly suggests that disease pathogenesis is antibodymediated and that patients would, therefore, respond to immunotherapy or corti costeroids, a prediction that has been recently validated in clinical studies [93] [94] [95] [96] [97] [98] . Studies using rat 30 and mouse 91 models support con clusions drawn from human studies. Exposure of rats to GAS antigens during immunization with GAS cell walls or plasma membranes leads to behaviours that are characteristic of Sydenham's chorea 30 . Immunized rats could not hold a food pellet or traverse a narrow beam and showed compulsive grooming behaviour 30 . These rats had IgG deposits in striatum, thalamus and frontal cortex with concomitant alterations in dopa mine and glutamate levels in cortex and basal ganglia. In addition, sera from Streptococcus spp.immunized rats have been shown to activate CAMK2 in a human neuronal cell line 30 , results which are similar to those obtained using sera from patients with Sydenham's chorea 38 . Removal of IgG from sera in these studies greatly diminished the CAMK2 activation in neuronal cells. In a mouse model, immune responses against GAS were also associated with motor and behavioural disturbances 91 . In both models, passive transfer of Streptococcus spp.specific antibodies directly into naive animals led to antibody deposits in the brain and concomitant behavioural changes 90, 99 . A study using the rat model has also addressed the effects of antibiotic therapy on behaviour and neurochemical changes. In this study, ampicillin treatment prevented the emergence of the motor symptoms and some of the behavioural alterations that were induced by GAS antigen exposure 100 .
Rheumatic carditis. Crossreactive antibodies have also been implicated in the pathogenesis of rheumatic cardi tis and recognize a variety of cardiac epitopes. Studies from the 1960s showed antibody deposition in human valve and myocardial tissues from patients who had died as a result of ARF or RHD 84 . These findings were later confirmed using mouse 40, 101 and human mAbs 32, 35 against GAS that reacted with both myocardial and val vular tissues. The human mAbs targeted striations in the myocardium and the endothelium of the valve, a finding that had been previously reported in studies using sera from patients with ARF or from animals immunized with GAS antigens 84, [102] [103] [104] . In support of the molecu lar mimicry hypothesis 105 , the targets of crossreactive antibodies were cardiac myosin in the myocardium and laminin 35 in the valve endothelium and basement mem brane, and these antibodies crossreacted with the group A carbohydrate or streptococcal M protein 35, 40, 101 . The crossreactive antibodies might also recognize glycosylated proteins or carbohydrate epitopes on the valve, which supports previous findings 106 showing an immunological relationship between GAS polysacchar ide and the structural glycoproteins of the heart valve 106 . This could help to explain why, in one study, the per sistence of elevated group A carbohydratespecific anti body responses in rheumatic carditis correlated with a poor prognosis of valvular heart disease 107 . Antibodies that target valve surfaces lead to inflammation and cel lular infiltration through the valve surface endocardium and/or endothelium 85 . The αhelical protein structures found in strepto coccal M proteins, cardiac myosin, keratin and laminin are involved in crossreactivity with antibodies that react to the group A carbohydrate epitope Nacetyl βdglucosamine 42, 101 . In addition, mutations in the αhelical M1 protein that stabilize irregularities in its αhelical coiled coil structure diminish its ability to be recognized by Streptococcus spp.specific anti bodies that crossreact with M protein and cardiac myosin 108 . This evidence suggests that αhelical protein epitopes and group A carbohydrate epitope Nacetyl βdglucosamine are important targets of crossreactive antibodies in ARF.
Active inflammation in rheumatic carditis is associ ated with humoral responses against specific epitopes of the S2 fragment of human cardiac myosin heavy chain 109 and these responses can be used to monitor disease progression and the effects of treatment 110 . S2 epitopes are similar among populations in which rheu matic carditis is endemic worldwide 109 , regardless of which M protein gene sequence (emm type) the GAS in the region carries. Repeated GAS throat (and possibly skin) infections are important in generating molecu lar mimicry, breaking immune tolerance and inducing epitope spreading, which leads to recognition of more epitopes in cardiac myosin and potentially other heart proteins. For example, epitopes shared among different streptococcal emm types in the B or C repeat regions of the streptococcal M proteins might prime the immune system against the heart during repeated streptococcal exposure and might eventually lead to RHD in suscep tible individuals 87, [111] [112] [113] . The A repeat regions of the GAS M proteins that are responsible for the typespecific protection against infection from each serotype are not shared with other M types and are not crossreactive. Sequences from the A repeat regions of the M protein serotypes have been used in group A streptococcal vac cines that show no evidence of crossreactivity in animal and human trials 32, 114 .
Collagen is an important structural protein in the heart valve and autoantibodies against collagen I are produced in ARF 115 , but these antibodies are not cross reactive. They might be produced as a result of immune responses against collagen after aggregation of collagen by certain streptococcal serotypes 116, 117 . Alternatively, they might also be due to the release of collagen from damaged valves during RHD 116 . Streptococcal proteins with similarity to collagen have been reported 118, 119 , although no immunological crossreactivity has been observed. This absence of crossreactivity raises the pos sibility of an alternative pathogenetic pathway in ARF that produces an antibodymediated response to colla gen in the valve that does not rely on molecular mimicry. As only cardiac myosin and M protein, but not collagen, have been shown to induce valvulitis in animal mod els 87, 120 , it is likely that molecular mimicry is important for breaking immune tolerance and for the initiation of rheumatic carditis, whereas the response to collagen probably occurs after this initial damage, as a result of exposure of the immune system to collagen -a process that continues during RHD.
Cellular immune responses in rheumatic carditis
The cellular autoimmune response in rheumatic carditis involves production of autoreactive T cells that infiltrate the valve and the myocardium, the activation of the val vular endothelium and the formation of Aschoff nodules in the valve.
Valvular endothelial activation.
IgG antibodies that react with valve endothelium lead to the upregula tion of vascular cell adhesion protein 1 (VCAM1) on the endothelial surface, which promotes infiltration of T cells through the activated endothelium into the valve 85, 116, 121 (FIGS 6, 8) . This endothelial activation also involves loss of normal endothelial cell arrangement and modifications to valvular collagen, which have been observed using scanning electron microscopy 122 . Both CD4 + and CD8 + T cells infiltrate the valves in ARF 123 but the CD4 + T cell subset predominates in the inflamed rheumatic valve 85 (FIG. 9) . Only autoreactive T cells that are continually activated by antigen (that is, valve pro teins) survive and remain in the valve to produce inflam matory cytokines and to cause valve injury. In ARF and RHD, lesions called Aschoff nodules or bodies can occur underneath the endocardium near to or at the valve but may also be seen directly in the myocardium, which usually heals in rheumatic carditis. These nodules are sites of granulomatous inflammation that contain both T cells and macrophages and they are formed as a result of an intense inflammatory process that is mainly mediated by CD4 + T cells 124 . VCAM1 also interacts with and upregulates numer ous other cell adhesion molecules, chemokines and their receptors. These include integrin α4β1 (also known as VLA4), intracellular adhesion molecule 1 (ICAM1), Pselectin, CCchemokine ligand 3 (CCL3; also known as MIP1α), CCL1 (also known as I309) and CXC chemokine ligand 9 (CXCL9; also known as MIG) 85, 113 . The autoimmune reaction in the valves is associated with 134 and peptides of the βchain of human cardiac light mero myosin region, which is the smaller of two subunits pro duced by tryptic digestion of human cardiac myosin 33, 34 . Peripheral blood and valveinfiltrating 34 human T cells react strongly against peptides of streptococcal M pro tein and human cardiac myosin. In animal models of RHD, the intact streptococcal M protein and peptides from A, B and C repeat regions of streptococcal M pro tein have been investigated for their potential to cause valvular heart disease. For instance, rat T cell lines that are specific for streptococcal M5 protein epitopes such as DKLKQQRDTLSTQKET 134 passively transfer valvulitis and upregulation of VCAM1 (REF. 135 ) to uninfected rats.
Pathological consequences of inflammation
The inflammatory cascade in ARF has structural and functional effects on various parts of the heart valves that can lead to acute inflammatory damage and ulti mately to RHD. This includes dilation of valve annulirings that surround the valve and that help close leaflets during systole -and elongation of chordae tendinae, which connect leaflets of the mitral and tricuspid valves to the left and right ventricles, respectively. Together these changes result in inadequate coaptation (that is, meeting) of the valve leaflets, which in turn causes regur gitation (that is, backwards leakage of blood through the valve when it closes) 136 . Further inflammation leads to fibrinous vegetations in the rough zone of the anterior leaflet and scarring of leaflets, which might ultimately lead to valvular stenosis, in which the valve becomes narrowed, stationary and is unable to fully open (FIG. 6) .
Diagnosis, screening and prevention Diagnosis
The diagnosis of ARF is made using clinical criteria (the Jones Criteria) and by excluding other differential diagnoses. The Jones Criteria were first established in 1944 (REF. 137 ) and since then have undergone multi ple modifications, revisions and updates, most recently in 2015 (REFS 1,138-141). The criteria are divided into major and minor manifestations (TABLE 2) . The diag nosis of ARF is made when the patient presents with two major manifestations or one major manifestation and at least two minor 1 manifestations. In addition, evi dence of preceding infection with GAS must be shown, which is usually done using streptococcal serology. The exceptions to these criteria are patients who present with chorea or indolent carditis because these manifestations might only become apparent months after the causa tive streptococcal infection and, therefore, additional manifestations might not be present and streptococcal serology testing might be normal 88 .
The most common presenting features of ARF are arthritis (75% of patients) and fever (>90% of patients). The arthritis of ARF is the most difficult diagnostic challenge because of the large number of differen tial diagnoses, especially in patients who present with an initial monoarthritis. In patients presenting with a single inflamed joint, it is important to exclude septic arthritis 142 . The arthritis of ARF is highly responsive to antiinflammatory drugs (aspirin and NSAIDs) and if the patient does not respond within 48-72 hours alter nate diagnoses should be considered. Subcutaneous nodules are small (0.5-2 cm in diameter), painless and round nodules that develop over bony prominences or extensor tendons, and erythema marginatum are bright pink, blanching macules or papules that spread outwards in a circular pattern, usually on the trunk and proximal limbs. Both are infrequent manifesta tions of ARF, occurring in less than 10% of patients 24, 50 . Nature Reviews | Disease Primers [145] [146] [147] [148] [149] . On the basis of these results, echocardio graphic evaluation for all patients who are suspected of having ARF is a new recommendation that has been included in the 2015 Jones Criteria. Both clinical and subclinical carditis fulfil a major criterion, even in the absence of classical auscultatory findings 1 (FIGS 10,11).
Chorea occurs in up to 30% of those who have ARF. It is characterized by involuntary and purposeless movements of the trunk, limbs and face. Chorea may also present on its own without other features of ARF and without evidence of a recent streptococcal infection. In this scenario, it is important to exclude other poten tial causes of chorea including drug reactions, systemic lupus erythematosus, Wilson disease and other diseases, and to carry out an echocardiogram because chorea is strongly associated with carditis.
The 2015 revision of the Jones Criteria was under taken by the American Heart Association in response to emerging data regarding differences in presentation of ARF between low and moderate-highrisk cohorts. Moderate-high risk is defined as coming from a popu lation with an ARF incidence of >2 per 100,000 school aged children per year or an all age RHD prevalence of >1 per 1,000 people per year. In moderate-high risk populations, monoarthritis in addition to the more clas sic polyarthritis can fulfil a major manifestation 1 . This Figure 6 | The GAS cross-reactive immune response in the heart. The heart is affected by antibodies (generated by B cells) against the group A carbohydrate binding to the surface of the valve and upregulating vascular cell adhesion molecule 1 (VCAM1) on the surface of the valve endothelium. The upregulation of VCAM1 allows T cells expressing integrin α4β1 (also known as VLA4) to adhere to the endothelium and to extravasate into the valve. The inner valve becomes infiltrated by T cells, primarily CD4 + T cells, and Aschoff bodies or granulomatous lesions form underneath the endocardium. Damage to the endothelium and infiltration of T cells into the valve remodels the valve structure, including the chordae tendineae, with malformation of the valve leading to regurgitation or stenosis of the valve. Breakdown of the valve releases collagen and results in further immune-mediated damage to the valve.
change is meant to increase the sensitivity of the criteria in areas where ARF remains endemic 24, 150, 151 and to main tain high specificity in lowrisk areas. These modifi cations were previously reflected in the Australian and New Zealand guidelines, which allow for less stringent findings among those at greatest risk 152, 153 . In many highrisk tropical areas, acute onset arthritis and fever can be caused by arboviral infections such as dengue, chikungunya and Ross River fever. These infections are important and common differential diagnoses for ARF. The risk of overdiagnosis of ARF can be reduced by test ing for these and other arboviral infections if possible, ensuring that streptococcal serology is positive when making a diagnosis of ARF (preferably by comparing acute and convalescent titres) and by completing a full workup for ARF that includes an echocardiogram.
Patients might present with established RHD rather than ARF. This is very common in resourcepoor settings in which patients frequently present with latestage RHD. For example, in a cohort of 309 patients with RHD in Uganda, none had a previous history of ARF 154 . The pres entation with de novo RHD is most often associated with symptoms of cardiac failure, although patients might also present with embolic stroke, infective endo carditis or arrhythmia (atrial fibrillation). There is evidence that RHD contributes to sudden cardiac death, probably as a result of cardiac arrhythmia 155 . RHD might also be diag nosed when a heart murmur is detected as part of routine care. Diagnosis of RHD in pregnant women is of particu lar importance because these patients present challenging issues in their management.
Prevention
Primordial prevention. Primordial prevention involves prophylactic strategies to avoid GAS infection. ARF is triggered by GAS pharyngitis and the GAS transmission is facilitated by close contact between people. Thus, liv ing conditions, knowledge regarding the importance of a sore throat caused by GAS and an understanding of the mechanisms of transmission are integral, both for the lay public and for health professionals, to the control of ARF. Studies carried out in Baltimore in a low resource inner city area outlined how the alleviation of household crowding could reduce the incidence of ARF independent of ethnic group 156 . Older ecological studies in the British army showed that bed spacing in crowded barracks was crucial to the control of ARF 157 . More recent studies lack analysis of the relative importance of primordial factors. However, in New Zealand, a devel oped country in which ARF clusters in poorer sections of the population, there is a clear association between ARF and socioeconomic deprivation. This association is shown using the New Zealand Deprivation Index, which combines 9 variables from the most recent national census including income, education, employment, accommodation and access to car and/or telephone 158 .
Primary prevention. Primary prevention aims to stop a GAS infection from causing ARF. ARF is preventable with appropriate healthcare by treating the preceding GAS pharyngitis with antibiotics (primary prophylaxis). As many cases of GAS pharyngitis might be asympto matic or cause only a mild sore throat, primary prophy laxis is only possible when a patient has symptoms of a sore throat that are sufficient to lead them to seek medical attention 2 . This presentation relies on access to healthcare with the knowledge, both on the part of the general population and the healthcare professionals, that treating a sore throat is important for ARF prevention. Highquality studies on the control of ARF through healthcare interventions such as use of longacting depot penicillin, which is a slowrelease formulation of peni cillin delivered by injection, were carried out soon after penicillin became available in the United States armed forces, in which ARF was occurring at very high rates 2 . Communitybased studies are, by their nature, less rigor ous and have suggested that widespread sore throat diagnosis and treatment might be effective in reducing ARF incidence in developing and developed countries, although it has yet to be definitively determined that primary prophylaxis alone will significantly reduce the incidence of ARF 114, 159, 160 . A randomized controlled trial (RCT) in New Zealand of a schoolbased sore throat intervention involving approximately 22,000 students determined the efficacy of active sore throat surveillance accompanied by throat swab confirmation and anti biotic treatment of GASpositive cases. Although this trial found a 28% reduction in ARF incidence in schools in which intervention had taken place, this result failed to reach statistical significance (P = 0.27) 161 . A largescale effectiveness evaluation of this intervention is underway in New Zealand and might provide definitive evidence of the potential for primary prophylaxis to reduce ARF incidence at a population level.
In the vast majority of published studies on primary prevention interventions, throat swabbing was not used to separate GAS pharyngitis from the more common viral pharyngitis. Rather, most of those who presented at clinics were treated with injectable longacting peni cillin. Clinical algorithms for better precision to avoid unnecessary antibiotic treatment for a viral pharyngitis have poor prediction 162 . Thus, culture of a throat swab, when it is possible to do so, is the best way to accurately diagnose GAS pharyngitis and to target antibiotic treat ment to patients whose sore throat is caused by a GAS infection in order to prevent ARF.
The persistence of a pharyngeal GAS is an impor tant risk factor for the development of ARF following an acute pharyngitis episode 163 . Early studies found that eradication of the microorganism can be achieved using injectable benzathine penicillin and subsequent studies have showed that satisfactory rates of eradication can also be achieved using 10 days of oral penicillin twice a day or 10 days of oral amoxicillin once a day [164] [165] [166] .
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Anti-transgenic chorea antibody Anti-tyrosine hydroxylase In order to reduce the risk of development of ARF, treat ment of GAS pharyngitis must be initiated within 9 days of onset of a sore throat 2, 156 . There are different reasons for choosing one of each of these three modalities. Use of other antimicrobial drugs is not supported; broadspec trum antibiotics are more expensive and, in the face of increasing resistance, not indicated for the majority of presentations. In some tropical areas where ARF is common, GAS carriage and GAS pharyngitis seem to be less common than in temperate areas, but impetigo (a superficial skin infection that results in sores and crust ing) caused by GAS occurs at very high levels 167 . In New Zealand, the GAS isolates associated with ARF come from classically skinassociated emm types and emm cluster types 168, 169 . These observations, and other data, have led to the hypothesis that GAS impetigo might con tribute to the pathogenesis of ARF 46, 167 , but no definitive link has been found between the two conditions and no studies on the treatment of GAS impetigo for primary prevention of ARF have been carried out.
Secondary prevention. The importance of secondary penicillin prophylaxis for prevention of recurrent ARF and progressive RHD cannot be overemphasized. This strategy has been proven in RCTs to prevent recurrence of ARF 170 and remains the single most important step of management of ARF. Intramuscular benzathine penicil lin (BPG) is superior to oral penicillin. There is strong evidence that secondary prophylaxis reduces the severity of RHD by preventing disease progression 171, 172 . Studies carried out in the midtwentieth century showed that 40-60% of patients with ARF progress to RHD [173] [174] [175] and that the rate of regression of mitral regurgitation increased from 20% to 70% after penicillin was introduced 173 . More recently, Lawrence and colleagues 10 studied 1,149 children with ARF (27.5% these children presented with carditis) in the Northern Territory, Australia, and reported that 35% of children with ARF developed RHD by 1 year and 61% had evidence of RHD by 10 years 10 . Of children that progressed to RHD, 14% showed heart failure at 1 year and 27% had heart failure at 5 years. In a multivariate analysis, the only factor found to be strongly associated with RHD incidence was age at first ARF episode (risk decreased by 2% per year of age). There was a suggestion that the risk of developing RHD after an ARF diagno sis was higher for Indigenous than for nonIndigenous people and for female than for male patients, but the confidence intervals for both hazard ratios included 1.0, which implies that there was no definitive evidence of difference in RHD risk between the groups.
Lue and colleagues 176 reported that patients receiving penicillin every fourth week, compared with those who received it every third week, were more likely to have undetectable serum penicillin levels between doses and were fivefold more likely to have prophylaxis failure 176 . However, contemporary data from New Zealand showed that ARF recurrences were rare among people who were fully adherent to a 4weekly BPG regimen -the rate of ARF recurrence in fully adherent individuals on a 28day regimen was 0.07 cases per 100 patient years. Failure on the prophylaxis programme (that is, recurrence of ARF, including in those who were less than fully adherent) was 1.4 cases per 100 patient years 177 . Patients without auscultation evidence of carditis are still at considerable risk of developing RHD. In one study, the preva lence of subclinical carditis following the first episode of ARF was 18% and half of the patients had persistence or deterioration of disease 2-23 months later 178 . Studies by Araujo and colleagues 179 and Pekpak and colleagues 180 reported that the proportion of patients with subclinical ARF who had persistence of carditis at least 1 year later was 72% and 55%, respectively. Efforts to optimize compliance with penicillin and to ensure a safe and adequate supply of the drug are crucial components of secondary prophylaxis 181 . Nonadherence to penicillin was strongly associated with recurrent ARF in a 2010 Brazilian study 182 . Many patients with RHD who live in developing countries seek medical atten tion too late to benefit from secondary prevention. For instance, one study found that Ugandan patients with RHD (n = 309) had a mean age of 30 years (range 15-60 years) and 85% had cardiovascular symptoms at initial presentation 154 . In addition, half of these patients had severe complications including heart failure, atrial flutter and/or fibrillation, pulmonary hypertension and stroke. None had ever been diagnosed with ARF or taken penicillin. Mitral stenosis is also more common at initial presentation in the developing world 183 . The appropriate duration of secondary prophylaxis depends on several factors. These include the time elapsed since the last episode of ARF (ARF recurrences occur more commonly in the first 5 years since the last episode) 177 , age (ARF recurrence is less common after the age of 25 years and uncommon after the age of 30 years) 177 , the presence or absence of carditis at pres entation and the severity of RHD at followup, and the environment (particularly the likelihood of ongoing Nature Reviews | Disease Primers exposure to GAS such as having young children in the household). On the basis of these factors, the recom mended duration of secondary prophylaxis is usually for a minimum of 10 years after the most recent episode of ARF or until age 18-21 years (whichever is longer) 184 . Recent guidelines recommend that those with moderate RHD continue prophylaxis until age 30-35 and those with severe RHD continue until age 40 (REFS 184, 185) .
Screening for RHD
Developing an effective screening strategy that could bridge the gap between the large number of patients with RHD who would benefit from secondary prophy laxis and the relatively small proportion of those who have a known ARF history has the potential to result in significant reduction of disease morbidity and mortality. Portable echocardiography machines have made large scale field echocardiography screening possible, even in remote settings. Multiple studies of schoolaged children have shown a significant (fivefold to fiftyfold) increase in detection of RHD by echocardiography screening com pared with auscul tation [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] . The prevalence of RHD in these studies ranged from 8-57 out of 1,000 children screened; if all of these cases represented true RHD, the disease might affect 62-78 million people worldwide and cause up to 1.4 million annual deaths 196 . Beaton and colleagues 192 found associations between lower socio economic status and older age with higher RHD preva lence. No patients with screeningdetected RHD recalled a history of ARF, underscoring the importance of screen ing as perhaps the only tool for early case detection in set tings in which ARF is uncommonly diagnosed and RHD presentations occur late in the illness. The World Heart Federation (WHF) published standardized screening guidelines in 2012 for the use of echocardiography without auscultation 197 . Using the WHF criteria, no definite RHD cases were found in a lowrisk group of Australian chil dren and borderline RHD was more common in highrisk than in lowrisk children, suggesting that definite RHD is likely to represent true disease and borderline RHD includes many children with true RHD 198 . Smartphonesize handheld echocardiography (HHE) offers hope for more efficient, mobile and cost effective screening. Beaton and colleagues 199 reported that HHE was highly sensitive and specific for distinguish ing between healthy individuals and those with RHD in a retrospective study of 125 Ugandan patients 199 . Moreover, HHE had good sensitivity (79%) and speci ficity (87%) for RHD detection, being most sensitive for definite RHD (97.9%) in a large prospective study of 1420 children in four schools in Gulu, Uganda 200 . Although few would argue against putting those with definite RHD on prophylaxis, management of borderline patients is unclear, given the risks associated with peni cillin and the stigma of being labelled with a chronic dis ease 201 . The population of patients with borderline RHD is heterogeneous and includes patients who are likely to have physiological mitral regurgitation and patients who are likely to develop progressive carditis 202 . There are no longterm followup data regarding this patient popu lation. In four studies looking at shortterm followup, 331 patients with subclinical RHD were followed for 4-27 months 186, 188, 203, 204 . Approximately twothirds of patients had no change and onethird had improvement or resolution. One study found disease progression in 10% of cases 188 . There was insufficient data on secondary prophy laxis or recurrence but one study that used prophylaxis for all patients found no disease progression 204 . Training frontline medical personnel is necessary for better access to screening. In Fiji, echocardiographic screening by two nurses had good sensitivity and speci ficity in detecting mitral regurgitation 205 . Screening children who do not attend school, older children and young adults 206 , and pregnant woman 14 might yield an even higher burden of disease. Studies are needed to determine if echocardiography screening can be cost effective 196 . A study using a Markov model found that echocardiography screening and secondary prophylaxis for patients with early evidence of RHD might be more cost effective than primary prophylaxis 207 . A public health approach that combines multiple modalities could result in a highly sensitive and specific screen that is affordable and could greatly affect resource allocation for prevention of ARF. The addition of bio markers to echocardiography screening programmes, such as Btype natriuretic peptides and antibodies against Streptococcus spp., that are specific for cardiac involve ment and immunological assays might result in more specific and sensitive screening programmes.
Management
ARF
High suspicion in geographic areas where ARF is endemic is vital. In any child or young person with an acutely painful and swollen joint, ARF should be con sidered in addition to septic arthritis and injury as well as rarer causes of their symptoms. Use of NSAIDs might mask the usual progression from this initial disease stage to polyarthritis, which is a hallmark of ARF. The major priority in the first few days after presentation with ARF Nature Reviews | Disease Primers a b is confirmation of the diagnosis. Ideally, all patients with suspected ARF should be hospitalized, primarily for an echocardiogram and other investigations as needed, such as a needle aspiration of the joint if septic arthritis is a possibility, inflammatory markers and a search for a preceding streptococcal throat infection (preferably by measuring streptococcal titres). A search for other causes of polyarthritis that are dependent on the geo graphic area, for example arboviral infections in the tropics, might be helpful if the echocardiogram remains normal for 3 weeks or more after the initial presentation. Hospitalization also provides an ideal opportunity for education about ARF, especially the need for secondary prophylaxis. The priorities in management of ARF relate to eradication of GAS from the throat, symptomatic treatment of arthritis and/or arthralgia and management of carditis and/or heart failure
.
To reliably eradicate GAS 208 , intramuscular BPG as a single dose or a full 10 days of oral penicillin or amoxicil lin should be given. The first dose of intramuscular BPG should also be given in hospital in association with edu cation about the importance of secondary prophylaxis, as the majority of patients are children 209 . Controlled studies have failed to show that treating ARF with peni cillin affects the outcome of rheumatic valvular lesions 1 year later 210, 211 .
In the prepenicillin era, prolonged bed rest in those with rheumatic carditis was associated with shorter dura tion of carditis, fewer relapses and less cardio megaly 212 . In the absence of contemporary studies, ambulation should be gradual and as tolerated in patients with severe acute valve disease, especially during the first 4 weeks, or until the serum Creactive protein level has normalized and the erythrocyte sedimentation rate has normal ized or significantly reduced. Those with milder or no carditis should only remain in bed as long as necessary to manage arthritis and other symptoms 153 .
Carditis. Longterm morbidity and mortality from ARF are mainly due to RHD, which in turn is mostly a func tion of the extent of acute cardiac involvement of ARF and the incidence of subsequent episodes of recurrent ARF. Corticosteroids reduce the inflammatory markers of ARF, especially fever and elevated acute phase reac tants and are widely used in severe acute carditis with heart failure, even though there is little objective data to prove that they augment the usual strategies such as bed rest, fluid restriction and cardiac medications 213, 214 . There is no evidence that corticosteroid use alters the severity of chronic valvular heart disease 1 year after ARF 213, 214 . However, previous studies of corticosteroid therapy for the treatment of ARF were mainly carried out in the 1950s and 1960s, before the advent of echo cardiography [213] [214] [215] . Valvular outcomes, which were primarily based on the presence of an apical systolic murmur, at 12month followup were not significantly improved and inflammation tended to rebound once steroid therapy was withdrawn. Despite this, cortico steroids are frequently used to treat severe carditis around the world 215, 216 . Intravenous immunoglobulin has been used in a RCT treatment study of ARF but no bene fit was shown 216 . There are no reliable data to support the use of other inflammatory modulators.
There is a strong argument for the need to carry out a multicentre RCT of corticosteroids versus place bo for ARF using echocardiographic end points for acute carditis (at 6 weeks) and chronic valvular disease (at 6 months to 1 year) 214 . Such a study would need to be powered to account for the natural improvement of carditis after the acute phase 216 but would provide an evidencebased approach to corticosteroid therapy for active rheumatic carditis. Similar multicentre studies of other immunomodulators, informed by an expanded understanding of ARF immunopathogenesis, could eventually be considered but there is no role for small, underpowered studies 217 .
Heart failure. An urgent echocardiogram and cardiology assessment are recommended for all patients with heart failure. Diuretics and fluid restriction are the mainstay of treatment. Angiotensinconverting enzyme (ACE) inhibitors are recommended for some patients with aortic regurgitation 209 . ACE inhibitors improve haemo dynamics by increasing cardiac output in patients with aortic regurgitation. They are indicated if there are symptoms or if there is left ventricular dysfunction, but should not be a substitute for surgery 218 . • Prolonged PR interval, after accounting for age variability (unless carditis is a major criterion)
As in the past Jones Criteria versions, it should be recalled that erythema marginatum and subcutaneous nodules are rarely 'stand alone' major criteria. In addition, joint manifestations can only be considered in either the major or minor categories but not both in the same patient. ARF, acute rheumatic fever; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RHD, rheumatic heart disease. *For all patient populations with evidence of preceding group A Streptococcus infection, diagnosis of initial ARF requires two major manifestations or one major plus two minor manifestations. Diagnosis of recurrent ARF requires either two major manifestations, one major and two minor manifestations or three minor manifestations. ‡ Annual ARF incidence of ≤2 per 100,000 school-aged children or all age RHD prevalence of ≤1 per 1,000 people per year. § Defined as echocardiographic valvulitis.
||
Polyarthralgia should only be considered as a major manifestation in moderate and high risk populations after exclusion of other causes. ¶ CRP value must be greater than the normal laboratory upper limit. In addition, as the ESR might evolve during the course of ARF, peak ESR values should be used.
Cardiac surgery is usually deferred until the acute inflammation has subsided so that the repair is techni cally easier and a more durable repair can be achieved. Rarely, chordae tendinae rupture leads to a flail leaflet, by which the unsecured section of the valve results in severe regurgitation and acute pulmonary oedema owing to a rapid rise in left atrial pressure. This condi tion is often misdiagnosed as pneumonia as the pulmo nary venous congestion is often unilateral. Such cases require emergency lifesaving surgery to repair the flail leaflet 219 . Even in the absence of a flail leaflet, urgent surgery might be indicated owing to torrential mitral or aortic regurgitation or both. The philosophy for car diac surgery in the young should always be to repair rather than to replace the mitral valve 220 . A recent retro spective report of 81 patients aged 3-19 years showed not only lower morbid ity (less endocarditis and no thrombo embolism) for repairs but also that the need for reoperation was not increased compared with the mitral valve replacement group 197 
.
Sydenham's chorea. Sydenham's chorea can be self limiting with resolution within weeks to months but some case series report the persistence of symptoms beyond 2 years 221 . Mild or moderate chorea does not require any specific treatment, aside from rest and a calm environment.
As chorea is often benign and selflimiting and medications against chorea medications are potentially toxic, treatment should only be considered if the move ments interfere substantially with normal activities, place the person at risk of injury or are extremely dis tressing to the patient, their family and their friends 209 . Aspirin therapy has no significant effect on rheumatic chorea 212 . Valproic acid and carbamazepine are now pre ferred to haloperidol, which was previously considered to be the firstline medical treatment for chorea 222, 223 . Valproic acid enhances neurotransmitters and stabil izes mood, and carbamazepine is a benzodiazepine anti convulsant and analgesic. A small, prospective com parison of these three agents concluded that valproic acid was the most effective 224 . However, because of the small potential for liver toxicity with valproic acid, it is recommended that carbamazepine be used initially for severe chorea requiring treatment and that valproic acid be considered for refractory cases 209 . Recent evidence from case series, a retrospective analysis and a single RCT suggest that corticosteroids can reduce symptom intensity and the time to remission in chorea, therefore short courses of prednisolone treatment can be con sidered for severe or refractory cases [93] [94] [95] [96] [97] [98] . The onset of chorea during pregnancy (chorea gravidarum) can be caused by ARF but there are many other causes of chorea that begin in pregnancy. Arthritis. The pain of mild arthritis or arthralgia and fever might respond to paracetamol alone, which should be used if the diagnosis is not confirmed (as early use of NSAIDs might mask the evolution of the typical migra tory polyarthritis). This is particularly important in areas in which echocardiography is unavailable, as the typical evolution of migratory polyarthritis is a hallmark of ARF. Aspirin has been the mainstay of treatment for decades, although published evidence also supports naproxen as an alternative for control of the arthritis of ARF. There is no similar published evidence for the use of other NSAIDs, although expert opinion supports the use of ibuprofen and this, as well as other NSAIDs and paracetamol, are recommended in guidelines for firstline treatment of arthritis pain 209 . Naproxen has similar analgesic potency as aspirin but, unlike aspirin 225, 226 , does not have the risk of the rare complication of Reye's syndrome, which is associ ated with multiorgan failure when aspirin is used to treat in viral infections in children. Aspirin and NSAIDs quickly control joint symptoms so they should be stopped as quickly as possible -while acknowledging that there is sometimes a need to prolong treatment somewhat to avoid 'rebound' joint symptoms on weaning -as there is no evidence that they have an influence on carditis.
Erythema marginatum and subcutaneous nodules.
Erythema marginatum and subcutaneous nodules are painless and transient manifestations. There is no speci fic treatment for either but local treatment might be required for ulceration that might rarely occur when the skin overlying the nodules is damaged.
RHD
Best practice RHD care involves secondary prevention with penicillin prophylaxis, timely reviews by a specialist experienced in RHD management, access to echocardio graphy to serially assess left ventricular function and valve function, adequate monitoring of anti coagulation therapy in patients with atrial fibrillation and/or mech anical prosthetic valves, access to oral healthcare and timely referral for heart surgery 209 .
The fundamental goals of longterm management of RHD are to prevent ARF recurrences (which lead to the progression of valve disease) and to monitor left ventri cular size and function. In many patients with mild or moderate RHD, in which the left ventricle is not at risk of failing, resolution of RHD is observed over time [227] [228] [229] . By contrast, in those with severe RHD, disease might progress owing to the irreversible damage of the valves. Pregnancy and childbirth. Ideally, women with known RHD should have a complete cardiac assessment before pregnancy 142 . In women who are already symptomatic with considerable RHD, consideration should be given to cardiac surgery before pregnancy to avoid severe mor bidity or even mortality as a result of the physiological changes of pregnancy on cardiac work. Mitral stenosis is particularly hazardous. Percutaneous balloon mitral valvotomy may be considered in women with anything more than mild mitral stenosis.
Women with moderate and severe RHD are at risk of obstetric complications such as preterm delivery and fetal complications such as fetal growth restriction. Cardiac complications can be compounded if pregnancy disorders such as preeclampsia or obstetric haemor rhage develop. Pregnant women with RHD should ideally be under the care of a multidisciplinary team with an obstetrician in collaboration with a cardiologist and/or an obstetric physician. Women with severe RHD should have their delivery at a referral centre that has onsite cardiology and intensivecare facilities.
Anticoagulation. Warfarin, a vitamin K antagonist, is the drug of choice for anticoagulation for patients with prosthetic heart valves, including those with both RHD and nonrheumatic valve disease. As the absorption of war farin is affected by diet, the international normalized ratio must be measured on a regular basis with adjust ments of the dose as required. Newer anticoagulants have been developed that dosedependently inhibit thrombin or activated factor X (such as dabigatran), but the efficacy and the safety of these newer agents are still being studied in patients with prosthetic valves and these agents are currently not recommended for use in this situation 209 . Anticoagulation is also indicated for those who develop atrial fibrillation.
Infective endocarditis. Although the American Heart Association guidelines no longer list RHD as an indi cation for antibiotic prophylaxis to prevent infective endocarditis, in other regions of the world where RHD and endocarditis are common, it is recommended that persons with established RHD or prosthetic valves should receive antibiotic prophylaxis before proce dures expected to produce bacteraemia, especially for Viridans streptocci 142, 209, 231 . Individuals who have a his tory of ARF but no valvular damage do not require antibiotic prophylaxis 209 .
Indications for cardiac surgery. Referral for cardiac surgery is indicated in adults with severe mitral regur gitation, severe aortic regurgitation or severe mitral steno sis 218 . Specific indications are evidencebased 218 ; valve regurgitation is assessed on the basis of symptoms and left ventricular size, and mitral stenosis is assessed on the basis of symptoms and valve gradient. Concomitant valve surgery for tricuspid regurgitation might be required. The body of evidence for the threshold for car diac surgery in children is minimal compared with the adult literature and is mainly based on published experi ence from New Zealand 220, [232] [233] [234] [235] . If the valve is judged to have a high likelihood of repair, surgery can be recom mended for moderate to severe mitral regurgitation with normal left ventricular size and function.
Mitral valve repair is the operation of choice for mitral regurgitation because of lower mortality and morbidity 236 . In adults, mitral valve repair has a higher reoperation rate than replacement 237 . When it is consid ered feasible to offer further surgery in the future, repair avoids the potentially fatal consequences of thrombo embolism with a prosthetic valve 238 . If the mitral valve is not suitable for repair, the option is valve replacement with either a mechanical valve prosthesis or a biopros thetic valve. Women of childbearing age who are plan ning a pregnancy should be offered a bioprosthetic valve rather than a prosthetic valve, even though the reoper ation rate will be higher, because the risk of warfarin to the fetus and the risk of heparin regimens to the patient remain high 239 . In most cases, referral for cardiac surgery or valvulo plasty is indicated for severe disease with symptoms and increasingly for asymptomatic disease with evidence of moderate to severe disease (TABLE 3 ). An exercise test 241 . Results indicated global impairment of quality of life in physi cal, emotional, social, school and psychosocial domains. Similarly, in Egypt, a sample of 400 parents of children with heart disease (32.5% with RHD) was compared with 400 parents of children with minor illness with an Arabic version of a standardized quality of life question naire (SF36) 242 . The parents of children with heart disease reported that their children had significantly (P < 0.001) different HRQOL with a reduction in general health and physical functioning and with role limitations as a result of physical, emotional and social problems. Factors determining HRQOL included age, severity of illness and the financial situation of families. An Arabic version of the Pediatric Quality of Life Inventory was also used to investigate the quality of life of 100 school aged Egyptian children with ARF. The majority of children recorded a neutral HRQOL and these results correlated well with maternal reports 243 . In Queensland, Australia, the parentreported CHQPF28 tool was used to score the quality of life outcomes of an RHD echo cardiography screening programme 244 . The study identi fied an adverse effect on quality of life in children with an abnormal screening result in the domains of 'general health perception' and 'parental impact -emotional' . Further work to use the PedsQL approach for young people identified with asymptomatic RHD in Nepal is underway 245 . A small number of qualitative studies support quanti tative HRQOL data. Anxiety about the medical, social, marital and financial outcomes of people living with RHD is a prominent theme worldwide 246, 247 . Studies investigating determinants of adherence to secondary prophylaxis have identified a range of logistical, rela tional and educational factors with the potential to influ ence both HRQOL and healthseeking behaviour 248, 249 . Strong themes expressed by patients in these studies are lack of empowerment, social and integrative challenges and poor coping mechanisms that are exacerbated by ill health.
The paucity of HRQOL data suggests that the nonmedical effect of RHD has been underexplored rela tive to the severity and the burden of disease world wide. One of the greatest challenges in the control of RHD is supporting people living with the disease to engage with ongoing prophylactic and therapeutic intervention. Greater attention to the lived experi ence of children, adults and communities with RHD has recently been prioritized by the RHD clinical and research community 250 . Priorities for further research are outlined in BOX 4. Improving the depth and the breadth of QOL studies is a crucial manifestation of this commit ment and ultimately an opportunity to optimize clinical care for people living with RHD.
Outlook With a few exceptions 227 , research into RHD has not received the backing of researchers from highresource countries who are supported by dedicated funding and contemporary methodological and technological tools. However, there has recently been a sustained increase in the focus on RHD among researchers in RHDendemic countries [251] [252] [253] . We believe that these efforts will con tribute to a reduction in ARF and/or RHD burden if they can be coordinated around three broad themes: effective implementation of known, evidencebased inter ventions, generation of new knowledge and inter ventions for RHD prevention and treatment, and advo cacy of RHD control efforts (BOX 5) . Although these represent distinct areas of focus, there is much overlap between these strategies and their integration into one concerted effort will be crucial to the success of ARF and/or RHD control.
Implementation of evidence-based interventions
It is now well known that there is poor use of estab lished preventive and control strategies in populations with RHD. As an example, recent data indicate that just more than half of eligible patients were receiving secondary antibiotic prophylaxis 52 , an intervention proven to reduce the recurrence of ARF 170 . The barri ers to uptake of simple, inexpensive treatments such as penicillin are numerous but mainly reflect the lack of systems to identify and to track patients with RHD in the community. Establishment of ARF and RHD regis ters for this purpose has been advocated as an important step towards disease control. However, there are cur rently only two countries (Australia and New Zealand) that have widespread registerbased RHD control pro grammes, perhaps reflecting the barriers to establish ing diseasespecific vertical control programmes in resourcepoor countries. Integration of ARF and RHD control efforts into existing disease prevention and con trol programmes is likely to be a more feasible option in these countries. Casefinding, referral and treatment monitoring as part of school health or other child health programmes is possible with education of providers and little additional funding. For example, RHD is one of the many diseases earmarked for screening and refer ral under a national child healthfocused programme in India (the Rashtriya Bal Swathya Karyakram initia tive) 254 . It might be possible to include the provision and the monitoring of secondary prophylaxis, and perhaps even sore throat detection and treatment, under this and similar schemes.
Generation of new knowledge and interventions
This is the most resourceintensive of the three outlined strategies and until recently has been the purview of researchers in highresource countries. In general, fund ing for neglected diseases is poor (<2% 218, 255 of healthcare research and development spending) and ARF and RHD research receives a mere 0.7% of these funds, the bulk of which (>90%) comes from public and philanthropic donors 256 . Thus, an essential first step in generating new knowledge is to convince funders (including the philan thropic arms of industry) to increase allocation to ARF and RHD research.
We believe that there are six key areas of research that will advance ARF and RHD control. First, contempor ary descriptions of the epidemiology of ARF and RHD are needed to identify demographic predispositions, to determine the rates of disease progression and adverse outcomes and to identify shortfalls and barriers to effect ive care. Such efforts are already underway 52, 253 . Second, there are little data on the place of tools, such as screening echocardiography and rapid streptococcal antigen tests, and strategies, such as blanket treatment of sore throats 160 , in diagnosis and management algorithms. Formal assess ment of these health technologies and practices, and their economic evaluation, are urgently needed for efficient resource allocation. Third, the development of a safe and effective vaccine against GAS will revolutionize the pri mary prevention of ARF and RHD. Efforts to accelerate the development of candidate vaccines are ongoing but will need greater coordination and funding 257 . Polyvalent vaccines based on typespecific M protein antigens and some vaccines based on the conserved regions of the GAS M protein seem promising 257, 258 . Fourth, the strong 
Advocacy
• Reliable data on disease burden and effects on populations • Adaptation of elements from advocacy models of the 'big three' diseases genetic predisposition to the development of RHD 259 has led investigators to design large genomewide associ ation studies to identify potential genetic markers. At least three large studies are underway and are likely to con tribute to our understanding of the genetics of ARF and RHD. Fifth, the use of contemporary tissue and plasma proteomic techniques might enhance our understand ing of the development and the progression of RHD and might help to identify pathophysiological pathways that are amenable to therapeutic modification 260, 261 . Finally, development of longer acting formulations of penicil lin might improve adherence to secondary prophylaxis. Awareness of this need has stimulated partnerships between academic researchers, industry and government, which are likely to lead to the development of marketable products in the near future.
Advocacy of ARF and RHD control efforts
Advocacy is of crucial importance in the case of ARF and RHD. RHD predominantly affects the poor and underprivileged in society, the very people whose voices are unlikely to be heard in the absence of strong advocates of their cause. Furthermore, in many RHD endemic countries, there is an increasingly common per ception that ARF and RHD are on the decline. This perception might be based on incomplete and often skewed data 262 and might potentially damage control efforts by understating the public health importance of the disease to policy makers. Accurate data on the bur den of the disease in the community and its effects on quality of life and loss of productivity are needed to make advocacy more credible and effective. Advocacy should therefore also place equal emphasis on raising awareness about the need for establishing systems for reliable assess ment of disease burden. Finally, the highly successful advocacy campaigns directed at the 'big three' diseases (HIV, tuberculosis and malaria) involved a large number of people and organizations beyond those in the health care profession. By contrast, advocacy for ARF and RHD control is mainly done by the few healthcare profession als working on the disease. Broader societal engagement in advocacy efforts, with the involvement of citizens' groups and nongovernmental organizations, is needed for the success of the ARF and RHD control agenda.
